NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
11.09
Dollar change
+0.30
Percentage change
2.78
%
Index- P/E- EPS (ttm)-1.49 Insider Own19.56% Shs Outstand16.03M Perf Week-13.73%
Market Cap6.35M Forward P/E- EPS next Y-25.20 Insider Trans0.00% Shs Float0.46M Perf Month13.91%
Enterprise Value2.52M PEG- EPS next Q-9.24 Inst Own13.08% Short Float5.81% Perf Quarter-20.18%
Income-15.75M P/S- EPS this Y16.15% Inst Trans- Short Ratio0.12 Perf Half Y-54.70%
Sales0.00M P/B63.51 EPS next Y33.33% ROA-192.51% Short Interest0.03M Perf YTD-52.97%
Book/sh0.17 P/C1.63 EPS next 5Y18.55% ROE-259.00% 52W High66.64 -83.36% Perf Year-82.08%
Cash/sh6.79 P/FCF- EPS past 3/5Y5.21% 57.27% ROIC-562.47% 52W Low7.56 46.64% Perf 3Y-83.07%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility16.40% 16.76% Perf 5Y-98.29%
Dividend TTM- EV/Sales- EPS Y/Y TTM16.50% Oper. Margin- ATR (14)2.13 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.90 Sales Y/Y TTM- Profit Margin- RSI (14)51.19 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.90 EPS Q/Q28.72% SMA207.77% Beta1.42 Target Price56.00
Payout- Debt/Eq0.02 Sales Q/Q- SMA500.39% Rel Volume0.03 Prev Close10.79
Employees7 LT Debt/Eq0.00 EarningsMay 14 BMO SMA200-51.59% Avg Volume231.65K Price11.09
IPODec 26, 2012 Option/ShortNo / Yes EPS/Sales Surpr.-77.78% - Trades Volume6,806 Change2.78%
Jul-01-25 08:14AM
Jun-25-25 07:00AM
Jun-24-25 12:52PM
Jun-13-25 08:00AM
Jun-02-25 08:00AM
08:00AM Loading…
May-14-25 08:00AM
May-08-25 08:00AM
Mar-25-25 08:00AM
Mar-20-25 08:00AM
Mar-18-25 08:00AM
Mar-13-25 07:30AM
Mar-12-25 04:15PM
Mar-04-25 08:00AM
Feb-25-25 08:00AM
Feb-05-25 08:00AM
08:00AM Loading…
Jan-13-25 08:00AM
Jan-08-25 08:00AM
Nov-22-24 08:36AM
Nov-12-24 08:00AM
Nov-11-24 08:00AM
Nov-07-24 08:00AM
Oct-23-24 08:00AM
Oct-22-24 08:00AM
Oct-15-24 08:00AM
Oct-10-24 08:00AM
Oct-08-24 08:00AM
Sep-05-24 08:30AM
Sep-03-24 08:00AM
Aug-12-24 08:00AM
Aug-07-24 07:00AM
08:00AM Loading…
Jun-11-24 08:00AM
Jun-04-24 08:00AM
Jun-03-24 08:00AM
May-30-24 08:00AM
May-29-24 08:00AM
May-22-24 08:00AM
May-08-24 12:54PM
08:00AM
Apr-11-24 07:30AM
Mar-28-24 08:00AM
Mar-25-24 08:30AM
Mar-18-24 08:00AM
Mar-13-24 07:30AM
Mar-04-24 07:30AM
Feb-15-24 08:00AM
Feb-08-24 08:00AM
Jan-04-24 08:00AM
Nov-06-23 04:01PM
08:00AM
Oct-31-23 09:01AM
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 08:00AM
Sep-06-23 08:05AM
Aug-14-23 08:00AM
Aug-10-23 08:45AM
Aug-07-23 08:00AM
Jun-15-23 08:00AM
May-31-23 08:30AM
May-11-23 07:00AM
May-09-23 08:00AM
May-01-23 08:00AM
Apr-24-23 09:00AM
Apr-20-23 04:05PM
Apr-19-23 09:28AM
08:05AM
Apr-17-23 08:00AM
Mar-22-23 08:00AM
Mar-17-23 08:00AM
Mar-15-23 08:05AM
Mar-13-23 08:05AM
Mar-07-23 08:05AM
Feb-14-23 08:00AM
Feb-07-23 08:05AM
Dec-13-22 07:30AM
Nov-10-22 04:05PM
Oct-18-22 07:00AM
Sep-06-22 09:02AM
Aug-08-22 08:00AM
Jun-09-22 07:00AM
Jun-03-22 07:00AM
May-23-22 08:00AM
May-19-22 07:00AM
May-18-22 04:15PM
May-12-22 08:00AM
May-03-22 12:20PM
Apr-20-22 07:00AM
Mar-23-22 07:00AM
Mar-21-22 07:00AM
Mar-17-22 07:00AM
Mar-07-22 07:00AM
Jan-14-22 09:38AM
Jan-05-22 07:00AM
Jan-03-22 07:00AM
Dec-01-21 08:00AM
Nov-15-21 07:00AM
Nov-04-21 10:51AM
Sep-15-21 07:00AM
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.